Back to Results

Crescent Biopharma Inc (CBIO)

Crescent Biopharma, Inc. is a NASDAQ-listed biotechnology company focused on researching and developing cancer therapy candidates in the United States. Its pipeline includes CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody in Phase 3 clinical testing for solid tumors, as well as CR-002 and CR-003. The company also has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. related to the development and commercialization of oncology therapeutics. Formerly known as GlycoMimetics, Inc., Crescent Biopharma was founded in 2024 and is headquartered in Waltham, Massachusetts.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NASDAQ-CBIO
$11.79
-8.9% Downside
Fair
$31.50
143.4% Upside
Bargain
Fair
0.0%
3.5x
46.6x
552.3 M
387.7 M
0.3%
63.2%
13.8
44.6%
Valuation • Fair Value

Crescent Biopharma Inc (NASDAQ-CBIO) Fair Value by Valuation Model

Review the available estimates for Crescent Biopharma Inc (NASDAQ-CBIO), including DCF Fair Value, EPV Fair Value, Comps Fair Value.

Primary Valuation Read

Fair Value

$11.79

Estimated downside of 8.9% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

DCF Fair Value

$14.60

Discounted cash flow valuation reference.

EPV Fair Value

$9.57

Earnings power value estimate.

Comps Fair Value

$11.11

Comparable-company valuation reference.

Analyst Price Target

$31.50

Analysts imply upside of 143.4%.

How to read these valuation models

Use the 6 available valuation references for Crescent Biopharma Inc (NASDAQ-CBIO) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Crescent Biopharma Inc (NASDAQ-CBIO)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

11.883 M

Current operating scale indicator.

Revenue Forecast

1,000 K

Forward revenue estimate.

EBITDA

-170 M

Current operating profitability reference.

How to read profitability and growth

This section helps investors review Crescent Biopharma Inc (NASDAQ-CBIO) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Crescent Biopharma Inc (NASDAQ-CBIO)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Fair

Mixed or neutral financial-health read.

Piotroski Score

3

Weak quality score that deserves closer review.

Altman Z-Score

13.8

Relatively strong balance-sheet zone.

FCF / Net Income

44.6%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Crescent Biopharma Inc (NASDAQ-CBIO). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Dividend Profile for Crescent Biopharma Inc (NASDAQ-CBIO)

Review the dividend metrics currently supported by the latest data.

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

The latest data indicates no current dividend yield for Crescent Biopharma Inc (NASDAQ-CBIO). No upcoming dividend amount or event date is currently available.

Stock Forecast • Technical Outlook

Crescent Biopharma Inc (NASDAQ-CBIO) Stock Forecast & Technical Outlook

Review Crescent Biopharma Inc (NASDAQ-CBIO) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for Crescent Biopharma Inc (NASDAQ-CBIO) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for Crescent Biopharma Inc (NASDAQ-CBIO) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Crescent Biopharma Inc (NASDAQ-CBIO) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Crescent Biopharma Inc (NASDAQ-CBIO) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Crescent Biopharma Inc (NASDAQ-CBIO) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Crescent Biopharma Inc (NASDAQ-CBIO)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, Crescent Biopharma Inc (NASDAQ-CBIO) has a Strong Buy consensus, with 7 buy, 0 hold and 0 sell recommendations in the current data set.

Buy 7
Hold 0
Sell 0
FAQ • Fast Investor Answers

Crescent Biopharma Inc (NASDAQ-CBIO) Stock FAQ

Data-supported answers about Crescent Biopharma Inc (NASDAQ-CBIO), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$11.79
Estimated downside 8.9%
Valuation Rating
Overvalued
Estimated downside of 8.9%
Analyst Target
$31.50
Implied upside 143.4%
Financial Health
Fair
Current financial-health read

The current fair value estimate for Crescent Biopharma Inc (NASDAQ-CBIO) is $11.79. This implies an estimated downside of 8.9% versus the current market price.

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 8.9% versus the current market price.

The available analyst price target for Crescent Biopharma Inc (NASDAQ-CBIO) is $31.50. The analyst target implies estimated upside of 143.4%.

The current financial health read for Crescent Biopharma Inc (NASDAQ-CBIO) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The latest available data indicates no current dividend yield for Crescent Biopharma Inc (NASDAQ-CBIO).

The current market capitalization listed for Crescent Biopharma Inc is 552.3 M.

The current enterprise value listed for Crescent Biopharma Inc is 387.7 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Crescent Biopharma Inc is NASDAQ-CBIO, and the stock is listed on NASDAQ.

Crescent Biopharma Inc (NASDAQ-CBIO) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Crescent Biopharma Inc is 0.3%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Crescent Biopharma Inc is 63.2%. Free float helps investors understand how much of the share base is available for public trading.

Similar Biotechnology Stocks View more on NASDAQ

Comparable companies from the same industry, limited to one security per issuer.

ABBV NYSE AbbVie Inc Fair Value Fair Market Cap 509.5 B
AMGN NASDAQ Amgen Inc Fair Value Fair Market Cap 249 B
GILD NASDAQ Gilead Sciences Inc Fair Value Overvalued Market Cap 207.9 B
VRTX NASDAQ Vertex Pharmaceuticals Inc Fair Value Fair Market Cap 137.5 B
MRNA NASDAQ Moderna Inc Fair Value Overvalued Market Cap 96.399 B
REGN NASDAQ Regeneron Pharmaceuticals Inc Fair Value Undervalued Market Cap 90.518 B
ARGX NASDAQ argenx NV ADR Fair Value Fair Market Cap 57.239 B
NTRA NASDAQ Natera Inc Fair Value Overvalued Market Cap 52.434 B
ONC NASDAQ BeOne Medicines AG DRC Fair Value Fair Market Cap 44.031 B
RVMD NASDAQ Revolution Medicines Inc Fair Value Fair Market Cap 38.077 B
BIIB NASDAQ Biogen Inc Fair Value Fair Market Cap 36.058 B
GMAB NASDAQ Genmab AS Fair Value Fair Market Cap 32.603 B
ROIV NASDAQ Roivant Sciences Ltd Fair Value Overvalued Market Cap 26.451 B
UTHR NASDAQ United Therapeutics Corporation Fair Value Fair Market Cap 24.093 B
INCY NASDAQ Incyte Corporation Fair Value Undervalued Market Cap 24.048 B
INSM NASDAQ Insmed Inc Fair Value Fair Market Cap 23.855 B
BNTX NASDAQ BioNTech SE Fair Value Fair Market Cap 21.287 B
ALNY NASDAQ Alnylam Pharmaceuticals Inc Fair Value Undervalued Market Cap 20.983 B
EXEL NASDAQ Exelixis Inc Fair Value Fair Market Cap 16.751 B
ASND NASDAQ Ascendis Pharma AS Fair Value Fair Market Cap 16.65 B